Key facts
- Ferryx’s last known valuation is $3.9M (Apr 2026).
- It has raised $960K; the latest was Seed Round ($200K) in Apr 2026.
- Notable investors include Innovate UK, EIT Food, University of Bristol, Deepbridge Capital, Evenlode Foundation — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Ferryx
- ·The full record, as it builds
Funding rounds
No funding rounds for Ferryx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ferryx
Developer of live biotherapeutics designed to treat inflammatory conditions in humans and animals. The company develops safe and effective bacterial products that prevent and treat gastrointestinal inflammation and conditions, including inflammatory bowel disease and irritable bowel syndrome, enabling the medical community and patients with safe and natural alternatives to traditional medications that have negative side effects.
- Sector
- Healthcare
- HQ
- Bristol, United Kingdom
- Founded
- 2019
- Employees
- 5
- Website
- ferryx.com/
- Ownership
- Privately Held (backing)
Ferryx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ferryx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ferryx in its N-PORT filings yet. We sweep new filings monthly.